Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Beroterkib in Advanced Solid Tumors
NCT03520075Phase 2Completed
- Sponsor
- Taiho Oncology
- Start
- May 2018
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of beroterkib in solid tumor (advanced stage), melanoma, non-small cell lung cancer (NSCLC), gynecological cancer, sponsored by Taiho Oncology. Started May 2018; status: completed.
02
Drugs
beroterkib
03
Conditions
solid tumor (advanced stage)melanomanon-small cell lung cancer (NSCLC)gynecological cancer
Beyond the preview
Go deeper on NCT03520075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520075.